CEACAM5 and cancer: And we have proposed a novel prognostic scoring system involving the serum levels of CEA, NLR, cancer antigen 19-9 (CA19-9), and lactate dehydrogenase (LDH) to evaluate whether it could predict survival benefits of PPTR in mCRC patients.